Literature DB >> 11529695

A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism.

S Middeldorp1, J R Meinardi, M M Koopman, E C van Pampus, K Hamulyák, J van Der Meer, M H Prins, H R Büller.   

Abstract

BACKGROUND: The factor V Leiden mutation is a common genetic defect associated with an increased risk for venous thromboembolism. The clinical implications for asymptomatic carriers of this mutation and, consequently, the usefulness of screening families in which a proband has both the mutation and venous thromboembolism are unclear.
OBJECTIVE: To determine the incidence of venous thromboembolism in asymptomatic carriers of the factor V Leiden mutation.
DESIGN: Prospective cohort study.
SETTING: University hospitals in the Netherlands. PARTICIPANTS: 470 asymptomatic carriers of the factor V Leiden mutation (234 men, 236 women; mean age, 43 years [range, 15 to 88 years]), 12 of whom were homozygous. Carriers were identified by screening the first-degree relatives (>15 years of age) of 247 symptomatic probands. MEASUREMENTS: Objectively diagnosed episodes of venous thromboembolism and the relationship between incidence and exposure to high-risk situations.
RESULTS: Nine venous thromboembolic events were observed in 1564 observation-years, resulting in an annual incidence of 0.58% (95% CI, 0.26% to 1.10%). The incidence of spontaneous venous thromboembolism was 0.26% (CI, 0.07% to 0.65%) per year; 3.5% (CI, 0.1% to 17.8%) per episode of surgery, trauma, or immobilization; 0.0% (CI, 0.0% to 19.5%) per pregnancy; 1.8% (CI, 0.4% to 5.2%) per year of oral contraceptive use; and 2.9% (CI, 0.8% to 15.3%) per year of use of hormone replacement therapy.
CONCLUSIONS: The absolute annual incidence of spontaneous venous thromboembolism in asymptomatic carriers of the factor V Leiden mutation is low and does not justify routine screening of the families of symptomatic patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529695     DOI: 10.7326/0003-4819-135-5-200109040-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  26 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Issues concerning the laboratory investigation of inherited thrombophilia.

Authors:  Armando Tripodi
Journal:  Mol Diagn       Date:  2005

Review 3.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

4.  Successful thrombolysis in patient with right heart thromboembolism : a case report and literature overview.

Authors:  E Koenigshausen; K Magnusson; E G Vester
Journal:  Clin Res Cardiol       Date:  2007-08-14       Impact factor: 5.460

5.  Impact of smoking during pregnancy on functional coagulation testing.

Authors:  Donna Dizon-Townson; Connie Miller; Valerija Momirova; Baha Sibai; Catherine Y Spong; George Wendel; Katharine Wenstrom; Philip Samuels; Steve Caritis; Yoram Sorokin; Menachem Miodovnik; Mary J O'Sullivan; Deborah Conway; Ronald J Wapner; Steven G Gabbe
Journal:  Am J Perinatol       Date:  2011-08-04       Impact factor: 1.862

Review 6.  A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives.

Authors:  Zanfina Ademi; C Simone Sutherland; Joris Van Stiphout; Jöelle Michaud; Goranka Tanackovic; Matthias Schwenkglenks
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

Review 7.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

8.  Cognitive and behavioural effects of genetic testing for thrombophilia.

Authors:  J Heshka; C Palleschi; B Wilson; J Brehaut; J Rutberg; H Etchegary; N Langlois; M Rodger; P S Wells
Journal:  J Genet Couns       Date:  2008-02-21       Impact factor: 2.537

9.  A pilot study to assess the feasibility of a multicenter cluster randomized trial for the management of asymptomatic persons with a thrombophilia.

Authors:  Philip S Wells; Martha L Louzada; Monica Taljaard; David R Anderson; Susan R Kahn; Nicole J Langlois; Julie Rutberg; Michael J Kovacs; Marc A Rodger
Journal:  J Genet Couns       Date:  2009-06-03       Impact factor: 2.537

Review 10.  Pulmonary embolism in pregnancy.

Authors:  E Conti; L Zezza; E Ralli; C Comito; L Sada; J Passerini; D Caserta; S Rubattu; C Autore; M Moscarini; M Volpe
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.